{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T17:29:17Z","timestamp":1793035757413,"version":"4.5.0"},"reference-count":76,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.ejphar.2025.177634","type":"journal-article","created":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T22:55:46Z","timestamp":1744757746000},"page":"177634","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Advancing therapeutic approaches and shaping future perspectives in the management of autosomal dominant polycystic kidney disease (ADPKD): Insights from clinical trials"],"prefix":"10.1016","volume":"997","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3654-2798","authenticated-orcid":false,"given":"Murali Krishna","family":"Moka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1565-3824","authenticated-orcid":false,"given":"Deepalaxmi","family":"Rathakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2494-6966","authenticated-orcid":false,"given":"D.K.","family":"Sriram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7101-8513","authenticated-orcid":false,"given":"Melvin","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2025.177634_bib1","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1093\/jjco\/hyz081","article-title":"Post-marketing observational study of everolimus in patients with unresectable or metastatic renal cell carcinoma in Japan","volume":"49","author":"Akaza","year":"2019","journal-title":"Jpn. J. Clin. Oncol."},{"key":"10.1016\/j.ejphar.2025.177634_bib2","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1681\/ASN.20213210S1391a","article-title":"Development of AL01211, a novel glucosylceramide synthase inhibitor, to treat autosomal dominant polycystic kidney disease (ADPKD)","volume":"32","author":"Babcock","year":"2021","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ejphar.2025.177634_bib3","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1002\/cpdd.1375","article-title":"Phase 1 healthy volunteer study of AL01211, an oral, non\u2010brain penetrant glucosylceramide synthase inhibitor, to treat fabry disease and type 1 gaucher disease","volume":"13","author":"Babcock","year":"2024","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"10.1016\/j.ejphar.2025.177634_bib4","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1007\/s40265-022-01745-9","article-title":"Drugs in clinical development to treat autosomal dominant polycystic kidney disease","volume":"82","author":"Bais","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.ejphar.2025.177634_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.xkme.2024.100802","article-title":"Tolvaptan and number needed to harm in autosomal dominant polycystic kidney disease","volume":"6","author":"Betts","year":"2024","journal-title":"Kidney Med"},{"key":"10.1016\/j.ejphar.2025.177634_bib6","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1093\/ckj\/sfaa232","article-title":"A randomized phase 1b cross-over study of the safety of low-dose pioglitazone for treatment of autosomal dominant polycystic kidney disease","volume":"14","author":"Blazer-Yost","year":"2021","journal-title":"Clin. Kidney J."},{"key":"10.1016\/j.ejphar.2025.177634_bib7","article-title":"Polycystic kidney disease: inheritance, pathophysiology, prognosis, and treatment","volume":"69","author":"Bremmer","year":"2010","journal-title":"Int. J. Nephrol. Renovascular Dis."},{"key":"10.1016\/j.ejphar.2025.177634_bib8","doi-asserted-by":"crossref","DOI":"10.2174\/1573402113666170427142815","article-title":"Effect of statin therapy on the progression of autosomal dominant polycystic kidney disease. A secondary analysis of the HALT PKD trials","volume":"13","author":"Brosnahan","year":"2018","journal-title":"Curr. Hypertens. Rev."},{"key":"10.1016\/j.ejphar.2025.177634_bib9","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1053\/j.ajkd.2021.06.026","article-title":"Metformin therapy in autosomal dominant polycystic kidney disease: a feasibility study","volume":"79","author":"Brosnahan","year":"2022","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.ejphar.2025.177634_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2017.00053","article-title":"Clinical trials in pediatric autosomal dominant polycystic kidney disease","volume":"5","author":"Cadnapaphornchai","year":"2017","journal-title":"Front. Pediatr."},{"key":"10.1016\/j.ejphar.2025.177634_bib11","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-48638-9","article-title":"Real-life use of tolvaptan in ADPKD: a retrospective analysis of a large Canadian cohort","volume":"13","author":"Calvaruso","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2025.177634_bib12","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/S0140-6736(13)61407-5","article-title":"Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial","volume":"382","author":"Caroli","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2025.177634_bib13","doi-asserted-by":"crossref","first-page":"303","DOI":"10.3390\/biomedicines9030303","article-title":"Oligonucleotide-based therapies for renal diseases","volume":"9","author":"Cart\u00f3n-Garc\u00eda","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.ejphar.2025.177634_bib14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0304813","article-title":"Somatostatin receptors in fibrotic myocardium","volume":"19","author":"Castillero","year":"2024","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2025.177634_bib15","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-67250-z","article-title":"Overview of clinical status, treatment, and long-term outcomes of pediatric autosomal-dominant polycystic kidney disease: a nationwide survey in Taiwan","volume":"14","author":"Chin","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2025.177634_bib16","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S0140-6736(18)32782-X","article-title":"Autosomal dominant polycystic kidney disease","volume":"393","author":"Cornec-Le Gall","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2025.177634_bib17","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1053\/j.ajkd.2018.02.347","article-title":"CRISPR gene editing in the kidney","volume":"71","author":"Cruz","year":"2018","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.ejphar.2025.177634_bib18","doi-asserted-by":"crossref","DOI":"10.1111\/eci.14147","article-title":"Serum bile acids associate with liver volume in polycystic liver disease and decrease upon treatment with lanreotide","volume":"54","author":"Dekker","year":"2024","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.ejphar.2025.177634_bib19","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-53064-x","article-title":"Effect of different types of statins on kidney function decline and proteinuria: a network meta-analysis","volume":"9","author":"Esmeijer","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2025.177634_bib20","doi-asserted-by":"crossref","DOI":"10.1093\/ndt\/gfae069.242","article-title":"#2119 long-term efficacy of tolvaptan therapy in patients with ADPKD","volume":"39","author":"Geertsema","year":"2024","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ejphar.2025.177634_bib21","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1111\/liv.12726","article-title":"Effect of lanreotide on polycystic liver and kidneys in autosomal dominant polycystic kidney disease: an observational trial","volume":"35","author":"Gevers","year":"2015","journal-title":"Liver Int."},{"key":"10.1016\/j.ejphar.2025.177634_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2023.107423","article-title":"Statin therapy in patients with early-stage autosomal dominant polycystic kidney disease: design and baseline characteristics","volume":"137","author":"Gitomer","year":"2024","journal-title":"Contemp. Clin. Trials"},{"key":"10.1016\/j.ejphar.2025.177634_bib23","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-032620","article-title":"Long-acting somatostatin analogue treatments in autosomal dominant polycystic kidney disease and polycystic liver disease: a systematic review and meta-analysis","volume":"10","author":"Griffiths","year":"2020","journal-title":"BMJ Open"},{"key":"10.1016\/j.ejphar.2025.177634_bib24","doi-asserted-by":"crossref","first-page":"523","DOI":"10.3390\/biomedicines13020523","article-title":"Advances and challenges in modeling autosomal dominant polycystic kidney disease: a focus on kidney organoids","volume":"13","author":"Gu","year":"2025","journal-title":"Biomedicines"},{"key":"10.1016\/j.ejphar.2025.177634_bib25","doi-asserted-by":"crossref","first-page":"82","DOI":"10.54097\/hset.v14i.1596","article-title":"The mechanism of autosomal dominant polycystic kidney disease (ADPKD)","volume":"14","author":"Guo","year":"2022","journal-title":"Highlights Sci. Eng. Technol."},{"key":"10.1016\/j.ejphar.2025.177634_bib26","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.ekir.2022.11.019","article-title":"Association of longitudinal urinary metabolic biomarkers with ADPKD severity and response to metformin in TAME-PKD clinical trial participants","volume":"8","author":"Hallows","year":"2023","journal-title":"Kidney Int. Reports"},{"key":"10.1016\/j.ejphar.2025.177634_bib27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0264129","article-title":"The efficacy of pioglitazone for renal protection in diabetic kidney disease","volume":"17","author":"Ho","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2025.177634_bib28","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1681\/ASN.2009121291","article-title":"Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease","volume":"21","author":"Hogan","year":"2010","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ejphar.2025.177634_bib29","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.2215\/CJN.13661119","article-title":"Pansomatostatin agonist pasireotide long-acting release for patients with autosomal dominant polycystic kidney or liver disease with severe liver involvement","volume":"15","author":"Hogan","year":"2020","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ejphar.2025.177634_bib30","doi-asserted-by":"crossref","first-page":"44","DOI":"10.2174\/1573402111309010008","article-title":"Experimental therapies and ongoing clinical trials to slow Down progression of ADPKD","volume":"9","author":"Irazabal","year":"2013","journal-title":"Curr. Hypertens. Rev."},{"key":"10.1016\/j.ejphar.2025.177634_bib31","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1093\/ndt\/gfs519","article-title":"mTOR inhibition in autosomal-dominant polycystic kidney disease (ADPKD): the question remains open","volume":"28","author":"Jardine","year":"2013","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ejphar.2025.177634_bib32","first-page":"1387","article-title":"Safety and effectiveness of ambrisentan in real clinical practice in pulmonary arterial hypertension: results from the Korean post\u2010marketing surveillance. Pharmacoepidemiol","volume":"32","author":"Jeon","year":"2023","journal-title":"Drug Saf."},{"key":"10.1016\/j.ejphar.2025.177634_bib33","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1007\/s10637-020-00926-1","article-title":"Open-label, single-center, phase I trial to investigate the mass balance and absolute bioavailability of the highly selective oral MET inhibitor tepotinib in healthy volunteers","volume":"38","author":"Johne","year":"2020","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.ejphar.2025.177634_bib34","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1038\/s41598-020-58382-z","article-title":"Renal cyst growth is attenuated by a combination treatment of tolvaptan and pioglitazone, while pioglitazone treatment alone is not effective","volume":"10","author":"Kanhai","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2025.177634_bib35","doi-asserted-by":"crossref","first-page":"322","DOI":"10.3904\/kjim.2022.376","article-title":"Recent updates in therapeutic approach using tolvaptan for autosomal dominant polycystic kidney disease","volume":"38","author":"Kim","year":"2023","journal-title":"Korean J. Intern. Med."},{"key":"10.1016\/j.ejphar.2025.177634_bib36","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.2215\/CJN.11331114","article-title":"Pravastatin therapy and biomarker changes in children and young adults with autosomal dominant polycystic kidney disease","volume":"10","author":"Klawitter","year":"2015","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ejphar.2025.177634_bib37","series-title":"Polycystic Kidney Disease","year":"2015"},{"key":"10.1016\/j.ejphar.2025.177634_bib38","doi-asserted-by":"crossref","first-page":"801","DOI":"10.21873\/invivo.13144","article-title":"Efficacy and safety of tolvaptan for patients with autosomal dominant polycystic kidney disease in real-world practice: a single institution retrospective study","volume":"37","author":"Masuda","year":"2023","journal-title":"In vivo (Brooklyn)"},{"key":"10.1016\/j.ejphar.2025.177634_bib39","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12882-017-0804-2","article-title":"A model to predict disease progression in patients with autosomal dominant polycystic kidney disease (ADPKD): the ADPKD outcomes model","volume":"19","author":"McEwan","year":"2018","journal-title":"BMC Nephrol."},{"key":"10.1016\/j.ejphar.2025.177634_bib40","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1001\/jama.2018.15870","article-title":"Effect of lanreotide on kidney function in patients with autosomal dominant polycystic kidney disease","volume":"320","author":"Meijer","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.ejphar.2025.177634_bib41","doi-asserted-by":"crossref","first-page":"36","DOI":"10.2215\/CJN.0000000000000022","article-title":"Tolvaptan for children and adolescents with autosomal dominant polycystic kidney disease","volume":"18","author":"Mekahli","year":"2023","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ejphar.2025.177634_bib42","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1186\/s12882-018-1176-y","article-title":"Association of plasma somatostatin with disease severity and progression in patients with autosomal dominant polycystic kidney disease","volume":"19","author":"Messchendorp","year":"2018","journal-title":"BMC Nephrol."},{"key":"10.1016\/j.ejphar.2025.177634_bib43","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1093\/ndt\/gfz054","article-title":"Somatostatin in renal physiology and autosomal dominant polycystic kidney disease","volume":"35","author":"Messchendorp","year":"2020","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ejphar.2025.177634_bib44","doi-asserted-by":"crossref","first-page":"692","DOI":"10.3390\/genes11060692","article-title":"Combined preimplantation genetic testing for autosomal dominant polycystic kidney disease: consequences for embryos available for transfer","volume":"11","author":"Mir Pardo","year":"2020","journal-title":"Genes"},{"key":"10.1016\/j.ejphar.2025.177634_bib45","doi-asserted-by":"crossref","first-page":"12253","DOI":"10.1096\/fj.201900217R","article-title":"Bardoxolone methyl analog attenuates proteinuria\u2010induced tubular damage by modulating mitochondrial function","volume":"33","author":"Nagasu","year":"2019","journal-title":"FASEB J."},{"key":"10.1016\/j.ejphar.2025.177634_bib46","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.ekir.2020.03.030","article-title":"Randomized clinical trial on the effect of bardoxolone methyl on GFR in diabetic kidney disease patients (TSUBAKI study)","volume":"5","author":"Nangaku","year":"2020","journal-title":"Kidney Int. Reports"},{"key":"10.1016\/j.ejphar.2025.177634_bib47","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.xkme.2019.11.009","article-title":"Advances in autosomal dominant polycystic kidney disease: a clinical review","volume":"2","author":"Nobakht","year":"2020","journal-title":"Kidney Med"},{"key":"10.1016\/j.ejphar.2025.177634_bib48","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.2215\/CJN.05850518","article-title":"Vascular dysfunction, oxidative stress, and inflammation in autosomal dominant polycystic kidney disease","volume":"13","author":"Nowak","year":"2018","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ejphar.2025.177634_bib49","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1053\/j.ajkd.2018.12.037","article-title":"Mineralocorticoid antagonism and vascular function in early autosomal dominant polycystic kidney disease: a randomized controlled trial","volume":"74","author":"Nowak","year":"2019","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.ejphar.2025.177634_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.conctc.2020.100635","article-title":"Curcumin therapy to treat vascular dysfunction in children and young adults with autosomal dominant polycystic kidney disease: design and baseline characteristics of participants","volume":"19","author":"Nowak","year":"2020","journal-title":"Contemp. Clin. Trials Commun"},{"key":"10.1016\/j.ejphar.2025.177634_bib51","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.740087","article-title":"Metabolic reprogramming and reconstruction: integration of experimental and computational studies to set the path forward in ADPKD","volume":"8","author":"Pagliarini","year":"2021","journal-title":"Front. Med."},{"key":"10.1016\/j.ejphar.2025.177634_bib52","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1038\/ki.2011.465","article-title":"Evaluation of urine biomarkers of kidney injury in polycystic kidney disease","volume":"81","author":"Parikh","year":"2012","journal-title":"Kidney Int."},{"key":"10.1016\/j.ejphar.2025.177634_bib53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.21926\/obm.genet.1804056","article-title":"Therapies for childhood polycystic kidney disease","volume":"2","author":"Patil","year":"2018","journal-title":"OBM Genet"},{"key":"10.1016\/j.ejphar.2025.177634_bib54","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002777","article-title":"Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): a randomized, double-blind, placebo-controlled, multicenter trial","volume":"16","author":"Perico","year":"2019","journal-title":"PLoS Med."},{"key":"10.1016\/j.ejphar.2025.177634_bib55","article-title":"Prolonged complete response to adjuvant tepotinib in a patient with newly diagnosed disseminated glioblastoma harboring mesenchymal-epithelial transition fusion","author":"Pham","year":"2024","journal-title":"Oncologist"},{"key":"10.1016\/j.ejphar.2025.177634_bib56","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1681\/ASN.2015010047","article-title":"Phosphodiesterase isoform regulation of cell proliferation and fluid secretion in autosomal dominant polycystic kidney disease","volume":"27","author":"Pinto","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ejphar.2025.177634_bib57","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2147\/DHPS.S338050","article-title":"Clinical utility and tolerability of tolvaptan in the treatment of autosomal dominant polycystic kidney disease (ADPKD). Drug","volume":"14","author":"Raina","year":"2022","journal-title":"Healthc. Patient Saf."},{"key":"10.1016\/j.ejphar.2025.177634_bib58","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1080\/21678707.2020.1804859","article-title":"Current and emerging treatment options to prevent renal failure due to autosomal dominant polycystic kidney disease","volume":"8","author":"Rangan G","year":"2020","journal-title":"Expert Opin. Orphan Drugs"},{"key":"10.1016\/j.ejphar.2025.177634_bib59","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s13023-016-0517-9","article-title":"Everolimus safety and efficacy for renal angiomyolipomas associated with Tuberous sclerosis complex: a Spanish expanded access trial","volume":"11","author":"Robles","year":"2016","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ejphar.2025.177634_bib60","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2147\/IJNRD.S125942","article-title":"Tolvaptan in the treatment of autosomal dominant polycystic kidney disease: patient selection and special considerations","volume":"11","author":"Sans-Atxer","year":"2018","journal-title":"Int. J. Nephrol. Renovascular Dis."},{"key":"10.1016\/j.ejphar.2025.177634_bib61","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.34067\/KID.0000000000000209","article-title":"Experimental models of polycystic kidney disease: applications and therapeutic testing","volume":"4","author":"Sieben","year":"2023","journal-title":"Kidney360"},{"key":"10.1016\/j.ejphar.2025.177634_bib62","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0257606","article-title":"Somatostatin analog therapy effectiveness on the progression of polycystic kidney and liver disease: a systematic review and meta-analysis of randomized clinical trials","volume":"16","author":"Suwabe","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2025.177634_bib63","series-title":"Informing Clinical Practice in Nephrology","first-page":"1","article-title":"Autosomal dominant polycystic kidney disease (ADPKD) clinical trials: a critical appraisal","author":"Swami","year":"2015"},{"key":"10.1016\/j.ejphar.2025.177634_bib64","doi-asserted-by":"crossref","first-page":"3404","DOI":"10.1681\/ASN.2016111232","article-title":"Bosutinib versus placebo for autosomal dominant polycystic kidney disease","volume":"28","author":"Tesar","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ejphar.2025.177634_bib65","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.2215\/CJN.01360210","article-title":"Prospects for mTOR inhibitor use in patients with polycystic kidney disease and hamartomatous diseases","volume":"5","author":"Torres","year":"2010","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ejphar.2025.177634_bib66","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.885457","article-title":"Comparative efficacy of pharmacological treatments for adults with autosomal dominant polycystic kidney disease: a systematic review and network meta-analysis of randomized controlled trials","volume":"13","author":"Tsukamoto","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.177634_bib67","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1053\/j.gastro.2019.04.018","article-title":"Lanreotide reduces liver growth in patients with autosomal dominant polycystic liver and kidney disease","volume":"157","author":"van Aerts","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejphar.2025.177634_bib68","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1056\/NEJMoa1003491","article-title":"Everolimus in patients with autosomal dominant polycystic kidney disease","volume":"363","author":"Walz","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2025.177634_bib69","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.910592","article-title":"Mesenchymal stem cells: a new therapeutic tool for chronic kidney disease","volume":"10","author":"Wang","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.ejphar.2025.177634_bib70","doi-asserted-by":"crossref","first-page":"S629","DOI":"10.1097\/01.tp.0000701988.45785.93","article-title":"Safety and efficacy of everolimus in maintenance kidney transplant patients: a 2-year post-marketing surveillance study in Japan","volume":"104","author":"Watanabe","year":"2020","journal-title":"Transplantation"},{"key":"10.1016\/j.ejphar.2025.177634_bib71","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1007\/s10637-023-01378-z","article-title":"Assessment of the potential of the MET inhibitor tepotinib to affect the pharmacokinetics of CYP3A4 and P-gp substrates","volume":"41","author":"Yalkinoglu","year":"2023","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.ejphar.2025.177634_bib72","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1200\/JCO.2024.42.16_suppl.3050","article-title":"ctDNA as a biomarker in phase II study of tepotinib in advanced solid cancers with MET exon 14 skipping mutation or amplification (KCSG AL19-17)","volume":"42","author":"Yang","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejphar.2025.177634_bib73","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/jcmm.14769","article-title":"Melatonin preconditioning is an effective strategy for mesenchymal stem cell\u2010based therapy for kidney disease","volume":"24","author":"Zhao","year":"2020","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.ejphar.2025.177634_bib74","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2022.1006427","article-title":"Non-coding RNAs as potential biomarkers and therapeutic targets in polycystic kidney disease","volume":"13","author":"Zheng","year":"2022","journal-title":"Front. Physiol."},{"key":"10.1016\/j.ejphar.2025.177634_bib75","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1053\/j.akdh.2023.01.003","article-title":"Autosomal dominant polycystic kidney disease therapies on the horizon","volume":"30","author":"Zhou","year":"2023","journal-title":"Adv. Kidney Dis. Heal."},{"key":"10.1016\/j.ejphar.2025.177634_bib76","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s10157-014-1059-x","article-title":"Effect of everolimus on polycystic liver volume in autosomal dominant polycystic kidney disease","volume":"19","author":"Zschiedrich","year":"2015","journal-title":"Clin. Exp. Nephrol."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299925003887?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299925003887?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T12:17:37Z","timestamp":1745842657000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299925003887"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":76,"alternative-id":["S0014299925003887"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2025.177634","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advancing therapeutic approaches and shaping future perspectives in the management of autosomal dominant polycystic kidney disease (ADPKD): Insights from clinical trials","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2025.177634","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"177634"}}